Comparative effectiveness of oral therapies targeting the prostacyclin pathway in pulmonary arterial hypertension: A systematic review and network meta-analysis

CONCLUSIONS: No differences in 6MWD change, clinical worsening reduction and adverse events rates were found among oral treprostinil and selexipag, resulting in similar efficacy and safety profiles.PMID:38309551 | DOI:10.1016/j.vph.2024.107280

Source: Vascular Pharmacology - February 3, 2024 Category: Drugs & Pharmacology Authors: Giovanna Manzi Marco Valerio Mariani Domenico Filomena Tommaso Recchioni Silvia Papa Gianmarco Scoccia Roberto Badagliacca Carmine Dario Vizza Source Type: research